Lets hope this news can transform into a good rise in share price.
"Stirling Products (ASX:STI) advises that it has recently received information from its current Distribution partner in South Africa (Afgri Operations Pty Limited) that the MCC has approved the application for R-salbutamol to be included under Section 36 of the Stock Remedy Act. The approval means that Afgri, on behalf of Stirling Products, can now conduct the necessary trials for registration and commercialisation under this Act rather than the more stringent MCC process."
I like the fact that they have the "easier" or quicker way to commercialisation
"The approval stipulated only two areas where data was specifically required to support the application; residue levels and dust control. “While we acknowledge that we will need to do trials in South Africa for residue levels, we are confident that this will not be an issue,” indicated Dr London. Previous studies have demonstrated that the effective residue levels in meat from animals that have been fed with R-salbutamol in the finishing stage, have a very large safety margin. Many kilograms of meat, regardless of whether it is chicken, beef or pork, needs to be consumed each day before getting close to the low residue levels that even humans with asthma are exposed to every day."
Looks pretty good :-)
STI Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held